{"disease":{"id":"escc","name":"escc"},"drugs":{"marketed":[{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07224750","title":"A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06478355","title":"Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT07147361","title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04210115","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":703,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03783442","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":649,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07266363","title":"Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06863831","title":"A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":536,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03430843","title":"A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":512,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07050576","title":"Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"The First Affiliated Hospital of Anhui Medical University","has_results":false},{"nct_id":"NCT07463573","title":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":466,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07417735","title":"SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":436,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT07488624","title":"Development and Multicenter Validation of a Novel Bio-Anatomical Staging System for Predicting Survival and Tailoring Adjuvant Therapy in ESCC After Neoadjuvant Chemoimmunotherapy.","phase":"","overall_status":"COMPLETED","enrollment_count":414,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT06710665","title":"Tumor Regression Grade As Predictor of Adjuvant Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT06952621","title":"Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":390,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT03957590","title":"A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07246330","title":"Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":340,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07152535","title":"Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":255,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06775652","title":"Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Yongtao Han","has_results":false},{"nct_id":"NCT06504615","title":"Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":208,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07236320","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Yongtao Han","has_results":false},{"nct_id":"NCT06698692","title":"Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06675201","title":"Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":165,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT07182149","title":"A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Normunity AccelCo, Inc.","has_results":false},{"nct_id":"NCT06912074","title":"Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03708328","title":"A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07067450","title":"Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT07531979","title":"Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":93,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04471480","title":"TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Dong Wang","has_results":false},{"nct_id":"NCT05342636","title":"A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04863079","title":"Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06531291","title":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT07016737","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":79,"lead_sponsor_name":"Ye jinjun","has_results":false},{"nct_id":"NCT07376876","title":"Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":73,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT07317609","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05221658","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT06709417","title":"A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07533305","title":"Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital of Henan University of Science and Technology","has_results":false},{"nct_id":"NCT06762158","title":"NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04839471","title":"BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT07272291","title":"A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03831828","title":"Correlation of Gene Status and Clinical Outcomes in ESCC","phase":"","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"LiuJunFeng","has_results":false},{"nct_id":"NCT07196345","title":"TAS-102 Plus Radiotherapy in Elderly ESCC","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT07039162","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Ming-Yu Lien","has_results":false},{"nct_id":"NCT07015489","title":"Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07339488","title":"Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT06603402","title":"Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT07080437","title":"An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Three Gorges Hospital of Chongqing University","has_results":false},{"nct_id":"NCT07142421","title":"A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07524374","title":"SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Zhigang Li","has_results":false},{"nct_id":"NCT07353541","title":"Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}